Search

Your search keyword '"Guo, Yabing"' showing total 36 results
Start Over Author "Guo, Yabing" Publication Year Range Last 3 years
36 results on '"Guo, Yabing"'

2. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Strasser, Simone, Thompson, Alexander, Roohullah, Aflah, Sievert, William, Andelkovic, Vladimir, Knox, Jennifer, Davies, Janine, Asselah, Jamil, Brahmania, Mayur, Majeed, Habeeb, Villanueva, Luis, Yanez Weber, Patricio, Garrido, Marcelo, Pizarro, Gonzalo Ignacio, Yanez, Nicolas, Xu, Ruocai, Ou, Shuangyan, Ren, Zhenggang, Pan, Hongming, Meng, Zhiqiang, Gu, Kangsheng, Chen, Xi, Zhang, Tao, Hao, Chunyi, Cao, Peiguo, Guo, Yabing, Qin, Shukui, Xiao, Juxiang, Fang, Weijia, Wang, Xin, Bai, Yuxian, Chen, Xiaoming, Yan, Dong, Zhao, Hong, Ying, Jieer, Bonilla, Carlos, Urrego, Olga, Zambrano, Angela, Lema, Mauricio, Restrepo Gutierrez, Juan Carlos, Cardona, Andres, Franco Millan, Sandra, Oscar, Madiedo, Ramos, Victor, Merle, Philippe, LeSourd, Samuel, Edeline, Julien, Bronowicki, Jean-Pierre, Bourliere, Marc, Cattan, Stephane, Bouattour, Mohamed, Mineur, Laurent, Regnault, Helene, Dauvois, Barbara, Schulze, Kornelius, Folprecht, Gunnar, Geier, Andreas, Waidmann, Oliver, Finkelmeier, Fabian, Venerito, Marino, Berres, Marie-Luise, Berg, Thomas, Lange, Christian, Schmidt, Hartmut, Waldschmidt, Dirk T, Bitzer, Michael, McDermott, Ray, Duffy, Austin, Masi, Gianluca, Zagonel, Vittorina, Tonini, Giuseppe, Piscaglia, Fabio, Gori, Stefania, Rizzo, Mimma, Biscaldi, Elisa, Foltran, Luisa, Cabibbo, Giuseppe, Ikeda, Masafumi, Kudo, Masatoshi, Aikata, Hiroshi, Numata, Kazushi, Marusawa, Hiroyuki, Kato, Naoya, Kurosaki, Masayuki, Morimoto, Manabu, Yamashita, Tatsuya, Koga, Hironori, Masaki, Tsutomu, Tateishi, Ryosuke, Inaba, Yoshitaka, Arakawa, Tomohiro, Suzuki, Yoshiyuki, Akua, Norio, Kobayashi, Masahiro, Hosaka, Tetsuya, Nakamuta, Makoto, Oza, Noriko, Kondo, Shunsuke, Furuse, Junji, Nagashima, Fumio, Kitano, Masayuki, Takaguchi, Koichi, Ryoo, Baek-Yeol, Lim, Ho Yeong, Kim, Jee Hyun, Kim, Tae-You, Kim, Han Sang, Hernandez Hernandez, Carlos, Motola Kuba, Daniel, Segura Gonzalez, Manuel, Cabrera Luviano, Jesus, Huitzil Melendez, Fidel, Ramirez Godinez, Francisco, Silva-Bravo, Fernando, Gane, Edward, Stedman, Catherine, Kwiatkowski, Mariusz, Wyrwicz, Lucjan, Nowakowska-Zajdel, Ewa, Kraj, Leszek, Janczewska, Ewa, Surma-Wlodarczyk, Renata, Breder, Valeriy, Sekacheva, Marina, Orlova, Rashida, Vasilyev, Alexander, Zukov, Ruslan, Vladimirov, Vladimir, Minguez, Beatriz, Matilla Pena, Ana, Fernandez Castroagudin, Javier, Romero Gomez, Manuel, Luis Lledo, Jose, Rubin, Angel, Garcia Sanchez, Araceli, Calleja Panero, Jose, Yu, Ming-Chin, Shen, Ying-Chun, Huang, Yi-Hsiang, Jeng, Long-Bin, Chang, Ting-Tsung, Yang, Sheng-Shun, Chen, Shinn-Cherng, Dechaphunkul, Arunee, Tanwandee, Tawesak, Leerapun, Apinya, Seker, Mesut, Harputluoglu, Hakan, Cicin, Irfan, Oksuzoglu, Berna, Bilici, Mehmet, Sezgin Goksu, Sema, Artac, Mehmet, Cil, Timucin, Yalcin, Suayib, Meyer, Tim, Sarker, Debashis, Rao, Ankit, Palmer, Daniel, Evans, Jeff, Hubner, Richard, Finn, Richard, Ulahannan, Susanna, Zakari, Ahmed, Feun, Lynn, Al-Rajabi, Raed, Sung, Max, He, Aiwu, Kardosh, Adel, Goyal, Lipika, Li, Daneng, Choi, Minsig, Posada, Juan, Dodlapati, Jyothi, Shroff, Rachna, Agrawal, Saurabh, Gopaluni, Srivalli, Akce, Mehmet, Alese, Olatunji, Baron, Ari, Dunne, Richard, Loaiza-Bonilla, Arturo, Frenette, Catherine, Llovet, Josep M, Kumada, Hiromitsu, Cheng, Ann-Lii, Galle, Peter R, Kaneko, Shuichi, Wang, Anran, Mody, Kalgi, Dutcus, Corina, Dubrovsky, Leonid, Siegel, Abby B, and Finn, Richard S

Published
2023
Full Text
View/download PDF

3. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author

Thompson, Alexander, Danta, Mark, Poursoltan, Pirooz, Kiberu, Andrew, Chittajallu, Renuka, Sood, Siddarth, Stauber, Rudolf, Pinter, Matthias, Peck-Radosavljevic, Markus, Decaestecker, Jochen, Cuyle, Pieter-Jan, Verset, Gontran, Van Vlierberghe, Hans, De Azevedo, Sergio, Andrade, Livia, Cunha Júnior, Ademar, Faria, Luiza, Yen, Cheng Tzu, Colli, Leandro, Asselah, Jamil, Kavan, Petr, Marquez, Vladimir, Brahmania, Mayur, Li, Qiang, Xing, Baocai, Guo, Yabing, Chen, Zhendong, Zhao, Haitao, Peng, Tao, Wang, Liming, Wang, Lu, Liu, Hongming, Wu, Feixiang, Qin, Lunxiu, Zheng, Qichang, Ying, Jieer, Li, Haitao, Wen, Tianfu, Qin, Shukui, Wen, Xiaoyu, Liu, Yunpeng, Chen, Minshan, Wang, Boqing, Bai, Yuxian, He, Yifu, Zhao, Hong, Zhou, Dong, Dai, Chaoliu, Teng, Gaojun, Cui, Shuzhong, Gao, Yi, Zhang, Xizhi, Lu, Zheng, Yin, Tao, Ding, Youming, Jia, Weidong, Xia, Yongxiang, Sun, Beicheng, Xia, Qiang, Yuan, Yufeng, Sun, Huichuan, Shi, Xuetao, Guzmán, Adrián, Corrales, Luis, Kral, Zdenek, Priester, Peter, Kubala, Eugen, Blanc, Jean Frederic, Bourliere, Marc, Peron, Jean Marie, Borg, Christophe, Bronowicki, Jean-Pierre, Ganne, Nathalie, Decaens, Thomas, Uguen, Thomas, Heurgue, Alexandra, Trojan, Joerg, Gonzalez-Carmona, Maria Angeles, Roderburg, Christoph, Ettrich, Thomas, Schotten, Clemens, Kandulski, Arne, Yau, Thomas, Chan, Lam, Scartozzi, Mario, Masi, Gianluca, Fanello, Silvia, Battezzati, Pier Maria, Leonardi, Francesco, Ghidini, Michele, Numata, Kazushi, Morimoto, Manabu, Hidaka, Hisashi, Tsuchiya, Kaoru, Yamashita, Tatsuya, Kato, Naoya, Kudo, Masatoshi, Hagihara, Atsushi, Koga, Hironori, Arakawa, Tomohiro, Nakamura, Ikuo, Kawamura, Yusuke, Kawaoka, Tomokazu, Shimada, Mitsuo, Hasegawa, Kiyoshi, Marusawa, Hiroyuki, Nakamura, Shinchiro, Hiraoka, Atsushi, Hayashi, Hiromitsu, Takeda, Shin, Lee, Han Chu, Paik, Seung Woon, Kim, Do Young, Lee, Jung Il, Jeong, Sook-Hyang, Kim, Won, Tak, Won Young, Heo, Jeong, Kim, Hyeyeong, Chon, Hong Jae, Cheong, Jaeyoun, Yoon, Seung Kew, Yoon, Jung-Hwan, Villalobos, Ricardo, Martinez Rodriguez, Jorge Luis, Oyervides Juarez, Victor, Hernández, Carlos Alberto, Klumpen, Heinz-Josef, de Vos-Geelen, Judith, Gane, Edward, Montenegro, Paola, Torres Mattos, Cesar, Janczewska, Ewa, Kawecki, Maciej, Nowakowska-Zajdel, Ewa, Fedenko, Alexander, Granov, Dmitrii, Alyasova, Anna, Sekacheva, Marina, Ledin, Evgeny, Samol, Jens, Toh, Han Chong, Calvo Campos, Mariona, Gomez Martin, Carlos, Lopez Lopez, Carlos, Muñoz Martin, Andres Jesus, Calleja Panero, Jose Luis, Montero Alvarez, Jose Luis, Reig Monzón, Maria, Delgado Mingorance, Ignacio, Minguez Rosique, Beatriz, Cheng, Ann Lii, Huang, Yi-Hsiang, Lin, Shi-Ming, Huang, Jee-Fu, Yu, Ming-Lung, Su, Wei-Wen, Korphaisarn, Krittiya, Maneenil, Kunlatida, Samdaengpan, Chayanee, Tharavichitkul, Ekkapong, Ozguroglu, Mustafa, Kose, Fatih, Harputluoglu, Hakan, Buchschacher, Gary, Thuluvath, Paul, Xiong, Henry, Patel, Mital, Gold, Philip, Li, Daneng, Brooks, Gabriel, Masood, Ashiq, Patel, Reema, George, Ben, Salgia, Reena, Manji, Gulam, Crow, Mary, Kaseb, Ahmed, Dugan, Matthew, Kadakia, Kunal, Kardosh, Adel, Gibbs, John, Shah, Ashesh, Burris III, Howard, Hsiehchen, David, Cheng, Ann-Lii, Kaseb, Ahmed O, Yopp, Adam C, Zhou, Jian, Nakamura, Shinichiro, Cha, Edward, Hack, Stephen P, Lian, Qinshu, Ma, Ning, Spahn, Jessica H, Wang, Yulei, Wu, Chun, and Chow, Pierce K H

Published
2023
Full Text
View/download PDF

4. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study

Author

Qin, Shukui, Chan, Stephen L, Cheng, Ann-Lii, Kaseb, Ahmed, Vogel, Arndt, Gu, Shanzhi, Bai, Yuxian, Ren, Zhenggang, Lin, Xiaoyan, Chen, Zhendong, Jia, Weidong, Jin, Yongdong, Guo, Yabing, Hu, Xiaohua, Meng, Zhiqiang, Liang, Jun, Cheng, Ying, Xiong, Jianping, Ren, Hong, Yang, Fang, Li, Wei, Chen, Yajin, Zeng, Yong, Sultanbaev, Alexander, Pazgan-Simon, Monika, Pisetska, Margaryta, Melisi, Davide, Ponomarenko, Dmitriy, Osypchuk, Yurii, Sinielnikov, Ivan, Yang, Tsai-Sheng, Liang, Xiao, Chen, Chunxia, Wang, Linna, Zhang, Mingxiang, Xu, Li, Yuan, Xianglin, Li, Da, Ying, Jierer, Zhang, Jingdong, Zhang, Tao, Gu, Kangsheng, He, Yifu, Hao, Ping, Jiang, Da, Zhang, Shu, Xing, Baocai, Zhang, Baihong, Wang, Dong, Zhai, Xiaofeng, Liang, Houjie, Cybulska-Stopa, Bozena, Dvorkin, Mikhail, Stroyakovskiy, Daniil, Nechaeva, Marina, Yen, Chia-Jui, Su, Wei-Wen, Chen, Yen-Hao, Bondarenko, Igor, Yang, Lin, Fang, Weijia, Gomez-Martin, Carlos, Ryu, Min-Hee, Kim, Han-Sang, Kim, Jee-Hyun, Zarubenkov, Oleg, Orlova, Rashida, Poddubskaya, Elena, Fadeeva, Natalia, Makarova, Yulia, Chao, Yee, Hung, Chao-Hung, Neffa, Maryna, Vynnychenko, Oleksandr, Burgoyne, Adam, Hao, Chunyi, Mohr, Raphael U, Diaz-Beveridge, Roberto, Feliu-Batlle, Jaime, Cubillo-Gracian, Antonio, Lee, Ann-Shing, Daniele, Bruno, Antonuzzo, Lorenzo, Sangiovanni, Angelo, Gasbarrini, Antonio, Scartozzi, Mario, Ahn, Mi Sun, Oh, Sung-Yong, Orlov, Sergey, Harputluoglu, Hakan, Oksuzoglu, Berna, Hsu, Chiun, Rau, Kun-Ming, Krechkovskyi, Oleksandr, Yareshko, Vladimir, Xiong, Henry, Lee, Fa-Chyi, Jiang, Yixing, Gabayan, Afshin, Crow, Mary, Van Steenkiste, Christophe, and Verset, Gontran

Published
2023
Full Text
View/download PDF

5. Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib (REACH-2 China): A randomised, multicentre, double-blind study

Author

Shao, Guoliang, Bai, Yuxian, Yuan, Xianglin, Chen, Xiaomin, Gu, Shanzhi, Gu, Kangsheng, Hu, Chunhong, Liang, Houjie, Guo, Yabing, Wang, Jufeng, Yen, Chia-Jui, Lee, Victor Ho-Fun, Wang, Chunxiao, Widau, Ryan C., Zhang, Wanli, Liu, Junjun, Zhang, Qiang, and Qin, Shukui

Published
2022
Full Text
View/download PDF

6. The efficacy and safety of transarterial chemoembolization combined with cadonilimab and lenvatinib for unresectable hepatocellular carcinoma: A phase II clinical trial.

Author

Liang, Guo, primary, Gu, Shanzhi, additional, Guo, Yabing, additional, Li, Hailiang, additional, Liu, Jingfeng, additional, Liu, Jibing, additional, Huang, Ming, additional, Zou, Yinghua, additional, Huang, Luke, additional, Zhang, Yangyang, additional, Liu, Ting, additional, Liu, Wei, additional, Wang, Zhongmin, additional, Li, Baiyong, additional, and Xia, Yu, additional

Published
2024
Full Text
View/download PDF

7. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

Author

Llovet, Josep M, primary, Kudo, Masatoshi, additional, Merle, Philippe, additional, Meyer, Tim, additional, Qin, Shukui, additional, Ikeda, Masafumi, additional, Xu, Ruocai, additional, Edeline, Julien, additional, Ryoo, Baek-Yeol, additional, Ren, Zhenggang, additional, Masi, Gianluca, additional, Kwiatkowski, Mariusz, additional, Lim, Ho Yeong, additional, Kim, Jee Hyun, additional, Breder, Valeriy, additional, Kumada, Hiromitsu, additional, Cheng, Ann-Lii, additional, Galle, Peter R, additional, Kaneko, Shuichi, additional, Wang, Anran, additional, Mody, Kalgi, additional, Dutcus, Corina, additional, Dubrovsky, Leonid, additional, Siegel, Abby B, additional, Finn, Richard S, additional, Strasser, Simone, additional, Thompson, Alexander, additional, Roohullah, Aflah, additional, Sievert, William, additional, Andelkovic, Vladimir, additional, Knox, Jennifer, additional, Davies, Janine, additional, Asselah, Jamil, additional, Brahmania, Mayur, additional, Majeed, Habeeb, additional, Villanueva, Luis, additional, Yanez Weber, Patricio, additional, Garrido, Marcelo, additional, Pizarro, Gonzalo Ignacio, additional, Yanez, Nicolas, additional, Ou, Shuangyan, additional, Pan, Hongming, additional, Meng, Zhiqiang, additional, Gu, Kangsheng, additional, Chen, Xi, additional, Zhang, Tao, additional, Hao, Chunyi, additional, Cao, Peiguo, additional, Guo, Yabing, additional, Xiao, Juxiang, additional, Fang, Weijia, additional, Wang, Xin, additional, Bai, Yuxian, additional, Chen, Xiaoming, additional, Yan, Dong, additional, Zhao, Hong, additional, Ying, Jieer, additional, Bonilla, Carlos, additional, Urrego, Olga, additional, Zambrano, Angela, additional, Lema, Mauricio, additional, Restrepo Gutierrez, Juan Carlos, additional, Cardona, Andres, additional, Franco Millan, Sandra, additional, Oscar, Madiedo, additional, Ramos, Victor, additional, LeSourd, Samuel, additional, Bronowicki, Jean-Pierre, additional, Bourliere, Marc, additional, Cattan, Stephane, additional, Bouattour, Mohamed, additional, Mineur, Laurent, additional, Regnault, Helene, additional, Dauvois, Barbara, additional, Schulze, Kornelius, additional, Folprecht, Gunnar, additional, Geier, Andreas, additional, Waidmann, Oliver, additional, Finkelmeier, Fabian, additional, Venerito, Marino, additional, Berres, Marie-Luise, additional, Berg, Thomas, additional, Lange, Christian, additional, Schmidt, Hartmut, additional, Waldschmidt, Dirk T, additional, Bitzer, Michael, additional, McDermott, Ray, additional, Duffy, Austin, additional, Zagonel, Vittorina, additional, Tonini, Giuseppe, additional, Piscaglia, Fabio, additional, Gori, Stefania, additional, Rizzo, Mimma, additional, Biscaldi, Elisa, additional, Foltran, Luisa, additional, Cabibbo, Giuseppe, additional, Aikata, Hiroshi, additional, Numata, Kazushi, additional, Marusawa, Hiroyuki, additional, Kato, Naoya, additional, Kurosaki, Masayuki, additional, Morimoto, Manabu, additional, Yamashita, Tatsuya, additional, Koga, Hironori, additional, Masaki, Tsutomu, additional, Tateishi, Ryosuke, additional, Inaba, Yoshitaka, additional, Arakawa, Tomohiro, additional, Suzuki, Yoshiyuki, additional, Akua, Norio, additional, Kobayashi, Masahiro, additional, Hosaka, Tetsuya, additional, Nakamuta, Makoto, additional, Oza, Noriko, additional, Kondo, Shunsuke, additional, Furuse, Junji, additional, Nagashima, Fumio, additional, Kitano, Masayuki, additional, Takaguchi, Koichi, additional, Kim, Tae-You, additional, Kim, Han Sang, additional, Hernandez Hernandez, Carlos, additional, Motola Kuba, Daniel, additional, Segura Gonzalez, Manuel, additional, Cabrera Luviano, Jesus, additional, Huitzil Melendez, Fidel, additional, Ramirez Godinez, Francisco, additional, Silva-Bravo, Fernando, additional, Gane, Edward, additional, Stedman, Catherine, additional, Wyrwicz, Lucjan, additional, Nowakowska-Zajdel, Ewa, additional, Kraj, Leszek, additional, Janczewska, Ewa, additional, Surma-Wlodarczyk, Renata, additional, Sekacheva, Marina, additional, Orlova, Rashida, additional, Vasilyev, Alexander, additional, Zukov, Ruslan, additional, Vladimirov, Vladimir, additional, Minguez, Beatriz, additional, Matilla Pena, Ana, additional, Fernandez Castroagudin, Javier, additional, Romero Gomez, Manuel, additional, Luis Lledo, Jose, additional, Rubin, Angel, additional, Garcia Sanchez, Araceli, additional, Calleja Panero, Jose, additional, Yu, Ming-Chin, additional, Shen, Ying-Chun, additional, Huang, Yi-Hsiang, additional, Jeng, Long-Bin, additional, Chang, Ting-Tsung, additional, Yang, Sheng-Shun, additional, Chen, Shinn-Cherng, additional, Dechaphunkul, Arunee, additional, Tanwandee, Tawesak, additional, Leerapun, Apinya, additional, Seker, Mesut, additional, Harputluoglu, Hakan, additional, Cicin, Irfan, additional, Oksuzoglu, Berna, additional, Bilici, Mehmet, additional, Sezgin Goksu, Sema, additional, Artac, Mehmet, additional, Cil, Timucin, additional, Yalcin, Suayib, additional, Sarker, Debashis, additional, Rao, Ankit, additional, Palmer, Daniel, additional, Evans, Jeff, additional, Hubner, Richard, additional, Finn, Richard, additional, Ulahannan, Susanna, additional, Zakari, Ahmed, additional, Feun, Lynn, additional, Al-Rajabi, Raed, additional, Sung, Max, additional, He, Aiwu, additional, Kardosh, Adel, additional, Goyal, Lipika, additional, Li, Daneng, additional, Choi, Minsig, additional, Posada, Juan, additional, Dodlapati, Jyothi, additional, Shroff, Rachna, additional, Agrawal, Saurabh, additional, Gopaluni, Srivalli, additional, Akce, Mehmet, additional, Alese, Olatunji, additional, Baron, Ari, additional, Dunne, Richard, additional, Loaiza-Bonilla, Arturo, additional, and Frenette, Catherine, additional

Published
2023
Full Text
View/download PDF

8. Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial

Author

Qin, Shukui, primary, Chen, Minshan, additional, Cheng, Ann-Lii, additional, Kaseb, Ahmed O, additional, Kudo, Masatoshi, additional, Lee, Han Chu, additional, Yopp, Adam C, additional, Zhou, Jian, additional, Wang, Lu, additional, Wen, Xiaoyu, additional, Heo, Jeong, additional, Tak, Won Young, additional, Nakamura, Shinichiro, additional, Numata, Kazushi, additional, Uguen, Thomas, additional, Hsiehchen, David, additional, Cha, Edward, additional, Hack, Stephen P, additional, Lian, Qinshu, additional, Ma, Ning, additional, Spahn, Jessica H, additional, Wang, Yulei, additional, Wu, Chun, additional, Chow, Pierce K H, additional, Thompson, Alexander, additional, Danta, Mark, additional, Poursoltan, Pirooz, additional, Kiberu, Andrew, additional, Chittajallu, Renuka, additional, Sood, Siddarth, additional, Stauber, Rudolf, additional, Pinter, Matthias, additional, Peck-Radosavljevic, Markus, additional, Decaestecker, Jochen, additional, Cuyle, Pieter-Jan, additional, Verset, Gontran, additional, Van Vlierberghe, Hans, additional, De Azevedo, Sergio, additional, Andrade, Livia, additional, Cunha Júnior, Ademar, additional, Faria, Luiza, additional, Yen, Cheng Tzu, additional, Colli, Leandro, additional, Asselah, Jamil, additional, Kavan, Petr, additional, Marquez, Vladimir, additional, Brahmania, Mayur, additional, Li, Qiang, additional, Xing, Baocai, additional, Guo, Yabing, additional, Chen, Zhendong, additional, Zhao, Haitao, additional, Peng, Tao, additional, Wang, Liming, additional, Liu, Hongming, additional, Wu, Feixiang, additional, Qin, Lunxiu, additional, Zheng, Qichang, additional, Ying, Jieer, additional, Li, Haitao, additional, Wen, Tianfu, additional, Qin, Shukui, additional, Liu, Yunpeng, additional, Wang, Boqing, additional, Bai, Yuxian, additional, He, Yifu, additional, Zhao, Hong, additional, Zhou, Dong, additional, Dai, Chaoliu, additional, Teng, Gaojun, additional, Cui, Shuzhong, additional, Gao, Yi, additional, Zhang, Xizhi, additional, Lu, Zheng, additional, Yin, Tao, additional, Ding, Youming, additional, Jia, Weidong, additional, Xia, Yongxiang, additional, Sun, Beicheng, additional, Xia, Qiang, additional, Yuan, Yufeng, additional, Sun, Huichuan, additional, Shi, Xuetao, additional, Guzmán, Adrián, additional, Corrales, Luis, additional, Kral, Zdenek, additional, Priester, Peter, additional, Kubala, Eugen, additional, Blanc, Jean Frederic, additional, Bourliere, Marc, additional, Peron, Jean Marie, additional, Borg, Christophe, additional, Bronowicki, Jean-Pierre, additional, Ganne, Nathalie, additional, Decaens, Thomas, additional, Heurgue, Alexandra, additional, Trojan, Joerg, additional, Gonzalez-Carmona, Maria Angeles, additional, Roderburg, Christoph, additional, Ettrich, Thomas, additional, Schotten, Clemens, additional, Kandulski, Arne, additional, Yau, Thomas, additional, Chan, Lam, additional, Scartozzi, Mario, additional, Masi, Gianluca, additional, Fanello, Silvia, additional, Battezzati, Pier Maria, additional, Leonardi, Francesco, additional, Ghidini, Michele, additional, Morimoto, Manabu, additional, Hidaka, Hisashi, additional, Tsuchiya, Kaoru, additional, Yamashita, Tatsuya, additional, Kato, Naoya, additional, Hagihara, Atsushi, additional, Koga, Hironori, additional, Arakawa, Tomohiro, additional, Nakamura, Ikuo, additional, Kawamura, Yusuke, additional, Kawaoka, Tomokazu, additional, Shimada, Mitsuo, additional, Hasegawa, Kiyoshi, additional, Marusawa, Hiroyuki, additional, Nakamura, Shinchiro, additional, Hiraoka, Atsushi, additional, Hayashi, Hiromitsu, additional, Takeda, Shin, additional, Paik, Seung Woon, additional, Kim, Do Young, additional, Lee, Jung Il, additional, Jeong, Sook-Hyang, additional, Kim, Won, additional, Kim, Hyeyeong, additional, Chon, Hong Jae, additional, Cheong, Jaeyoun, additional, Yoon, Seung Kew, additional, Yoon, Jung-Hwan, additional, Villalobos, Ricardo, additional, Martinez Rodriguez, Jorge Luis, additional, Oyervides Juarez, Victor, additional, Hernández, Carlos Alberto, additional, Klumpen, Heinz-Josef, additional, de Vos-Geelen, Judith, additional, Gane, Edward, additional, Montenegro, Paola, additional, Torres Mattos, Cesar, additional, Janczewska, Ewa, additional, Kawecki, Maciej, additional, Nowakowska-Zajdel, Ewa, additional, Fedenko, Alexander, additional, Granov, Dmitrii, additional, Alyasova, Anna, additional, Sekacheva, Marina, additional, Ledin, Evgeny, additional, Samol, Jens, additional, Toh, Han Chong, additional, Calvo Campos, Mariona, additional, Gomez Martin, Carlos, additional, Lopez Lopez, Carlos, additional, Muñoz Martin, Andres Jesus, additional, Calleja Panero, Jose Luis, additional, Montero Alvarez, Jose Luis, additional, Reig Monzón, Maria, additional, Delgado Mingorance, Ignacio, additional, Minguez Rosique, Beatriz, additional, Cheng, Ann Lii, additional, Huang, Yi-Hsiang, additional, Lin, Shi-Ming, additional, Huang, Jee-Fu, additional, Yu, Ming-Lung, additional, Su, Wei-Wen, additional, Korphaisarn, Krittiya, additional, Maneenil, Kunlatida, additional, Samdaengpan, Chayanee, additional, Tharavichitkul, Ekkapong, additional, Ozguroglu, Mustafa, additional, Kose, Fatih, additional, Harputluoglu, Hakan, additional, Buchschacher, Gary, additional, Thuluvath, Paul, additional, Xiong, Henry, additional, Patel, Mital, additional, Gold, Philip, additional, Li, Daneng, additional, Brooks, Gabriel, additional, Masood, Ashiq, additional, Patel, Reema, additional, George, Ben, additional, Salgia, Reena, additional, Manji, Gulam, additional, Crow, Mary, additional, Kaseb, Ahmed, additional, Dugan, Matthew, additional, Kadakia, Kunal, additional, Kardosh, Adel, additional, Gibbs, John, additional, Shah, Ashesh, additional, and Burris III, Howard, additional

Published
2023
Full Text
View/download PDF

9. Evaluation of an artificial intelligence-based clinical trial matching system in Chinese patients with hepatocellular carcinoma: a retrospective study.

Author

Wang, Kunyuan, Cui, Hao, Zhu, Yun, Hu, Xiaoyun, Hong, Chang, Guo, Yabing, An, Lingyao, Zhang, Qi, and Liu, Li

Abstract

Background: Artificial intelligence (AI)-assisted clinical trial screening is a promising prospect, although previous matching systems were developed in English, and relevant studies have only been conducted in Western countries. Therefore, we evaluated an AI-based clinical trial matching system (CTMS) that extracts medical data from the electronic health record system and matches them to clinical trials automatically. Methods: This study included 1,053 consecutive inpatients primarily diagnosed with hepatocellular carcinoma who were referred to the liver tumor center of an academic medical center in China between January and December 2019. The eligibility criteria extracted from two clinical trials, patient attributes, and gold standard were decided manually. We evaluated the performance of the CTMS against the established gold standard by measuring the accuracy, sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and run time required. Results: The manual reviewers demonstrated acceptable interrater reliability (Cohen’s kappa 0.65–0.88). The performance results for the CTMS were as follows: accuracy, 92.9–98.0%; sensitivity, 51.9–83.5%; specificity, 99.0–99.1%; PPV, 75.7–85.1%; and NPV, 97.4–98.9%. The time required for eligibility determination by the CTMS and manual reviewers was 2 and 150 h, respectively. Conclusions: We found that the CTMS is particularly reliable in excluding ineligible patients in a significantly reduced amount of time. The CTMS excluded ineligible patients for clinical trials with good performance, reducing 98.7% of the work time. Thus, such AI-based systems with natural language processing and machine learning have potential utility in Chinese clinical trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Author

Qin, Shukui, primary, Kudo, Masatoshi, additional, Meyer, Tim, additional, Bai, Yuxian, additional, Guo, Yabing, additional, Meng, Zhiqiang, additional, Satoh, Taroh, additional, Marino, Donatella, additional, Assenat, Eric, additional, Li, Songzi, additional, Chen, Yaxi, additional, Boisserie, Frederic, additional, Abdrashitov, Ramil, additional, Finn, Richard S., additional, Vogel, Arndt, additional, and Zhu, Andrew X., additional

Published
2023
Full Text
View/download PDF

11. Abstract CT150: Result of an open-label phase 2 trial of dual TORC1/TORC2 inhibitor onatasertib (ATG-008) in HBV+ advanced hepatocellular carcinoma (HCC) subjects who have received at least one prior line of systemic therapy (TORCH)

Author

Qin, Shukui, primary, Lin, Xiaoyan, additional, Meng, Zhiqaing, additional, Ren, Zhenggang, additional, Bai, Yuxian, additional, Gu, Shanzhi, additional, Zheng, Li, additional, Li, Qiu, additional, Oh, Sun-Yong, additional, Guo, Yabing, additional, Kang, Yoong-Koo, additional, Kao, Wei-Yu, additional, Li, Wei, additional, Yoon, Jung-Hwan, additional, Zhang, Helong, additional, Chen, Pei-Jer, additional, Yang, Tsai-Sheng, additional, Heo, Jeong, additional, Zheng, Zhendong, additional, Xie, Hui, additional, and Yu, Zhinuan, additional

Published
2023
Full Text
View/download PDF

13. Report of adverse events of special interest (AESIs) for sintilimab plus a bevacizumab biosimilar (IBI305) in unresectable hepatocellular carcinoma.

Author

Ren, Zhenggang, primary, Xu, Jianming, additional, Bai, Yuxian, additional, Xu, Aibing, additional, Cang, Shundong, additional, Du, Chengyou, additional, Liu, Baorui, additional, Li, Qiu, additional, Lu, Yinying, additional, Chen, Yajin, additional, Shao, Guoliang, additional, Guo, Yabing, additional, Chen, Zhendong, additional, and Fan, Jia, additional

Published
2023
Full Text
View/download PDF

14. ORIENT-32: Updated characterization of response to sintilimab plus bevacizumab biosimilar (IBI305) vs sorafenib for unresectable hepatocellular carcinoma.

Author

Ren, Zhenggang, primary, Xu, Jianming, additional, Bai, Yuxian, additional, Xu, Aibing, additional, Cang, Shundong, additional, Du, Chengyou, additional, Liu, Baorui, additional, Li, Qiu, additional, Lu, Yinying, additional, Chen, Yajin, additional, Shao, Guoliang, additional, Guo, Yabing, additional, Chen, Zhendong, additional, and Fan, Jia, additional

Published
2023
Full Text
View/download PDF

15. Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study.

Author

Ren, Zhenggang, primary, Guo, Yabing, additional, Bai, Yuxian, additional, Ying, Jieer, additional, Meng, Zhiqiang, additional, Chen, Zhendong, additional, Gu, Shanzhi, additional, Zhang, Jingdong, additional, Liang, Jun, additional, Hou, Xinfang, additional, Li, Wei, additional, Xu, Aibing, additional, Hao, Chunyi, additional, Zhang, Jian, additional, Xing, Ruijun, additional, Zhang, Xinyu, additional, Zhang, Dan, additional, and Chan, Stephen Lam, additional

Published
2023
Full Text
View/download PDF

16. Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)

Author

Zhou, Jian, primary, Sun, Huichuan, additional, Wang, Zheng, additional, Cong, Wenming, additional, Zeng, Mengsu, additional, Zhou, Weiping, additional, Bie, Ping, additional, Liu, Lianxin, additional, Wen, Tianfu, additional, Kuang, Ming, additional, Han, Guohong, additional, Yan, ZhiPing, additional, Wang, Maoqiang, additional, Liu, Ruibao, additional, Lu, Ligong, additional, Ren, Zhenggang, additional, Zeng, ZhaoChong, additional, Liang, Ping, additional, Liang, Changhong, additional, Chen, Min, additional, Yan, Fuhua, additional, Wang, Wenping, additional, Hou, Jinlin, additional, Ji, Yuan, additional, Yun, Jingping, additional, Bai, Xueli, additional, Cai, Dingfang, additional, Chen, Weixia, additional, Chen, Yongjun, additional, Cheng, Wenwu, additional, Cheng, Shuqun, additional, Dai, Chaoliu, additional, Guo, Wenzhi, additional, Guo, Yabing, additional, Hua, Baojin, additional, Huang, Xiaowu, additional, Jia, Weidong, additional, Li, Qiu, additional, Li, Tao, additional, Li, Xun, additional, Li, Yaming, additional, Li, Yexiong, additional, Liang, Jun, additional, Ling, Changquan, additional, Liu, Tianshu, additional, Liu, Xiufeng, additional, Lu, Shichun, additional, Lv, Guoyue, additional, Mao, Yilei, additional, Meng, Zhiqiang, additional, Peng, Tao, additional, Ren, Weixin, additional, Shi, Hongcheng, additional, Shi, Guoming, additional, Shi, Ming, additional, Song, Tianqiang, additional, Tao, Kaishan, additional, Wang, Jianhua, additional, Wang, Kui, additional, Wang, Lu, additional, Wang, Wentao, additional, Wang, Xiaoying, additional, Wang, Zhiming, additional, Xiang, Bangde, additional, Xing, Baocai, additional, Xu, Jianming, additional, Yang, Jiamei, additional, Yang, Jianyong, additional, Yang, Yefa, additional, Yang, Yunke, additional, Ye, Shenglong, additional, Yin, Zhenyu, additional, Zeng, Yong, additional, Zhang, Bixiang, additional, Zhang, Boheng, additional, Zhang, Leida, additional, Zhang, Shuijun, additional, Zhang, Ti, additional, Zhang, Yanqiao, additional, Zhao, Ming, additional, Zhao, Yongfu, additional, Zheng, Honggang, additional, Zhou, Ledu, additional, Zhu, Jiye, additional, Zhu, Kangshun, additional, Liu, Rong, additional, Shi, Yinghong, additional, Xiao, Yongsheng, additional, Zhang, Lan, additional, Yang, Chun, additional, Wu, Zhifeng, additional, Dai, Zhi, additional, Chen, Minshan, additional, Cai, Jianqiang, additional, Wang, Weilin, additional, Cai, Xiujun, additional, Li, Qiang, additional, Shen, Feng, additional, Qin, Shukui, additional, Teng, Gaojun, additional, Dong, Jiahong, additional, and Fan, Jia, additional

Published
2023
Full Text
View/download PDF

18. AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein-1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus TIS plus BAT1706 as first-line (1L) treatment for advanced hepatocellular carcinoma (HCC).

Author

Fan, Jia, primary, Ren, Zhenggang, additional, Hsu, Chiun, additional, Guo, Yabing, additional, Song, Tianqiang, additional, Wang, Wentao, additional, Chao, Yee, additional, Gao, Yujuan, additional, Li, Vincent, additional, Ferro, Salvatore, additional, and Yen, Chia-Jui, additional

Published
2022
Full Text
View/download PDF

19. Unexpected high retention of 15N-labeled nitrogen in a tropical legume forest under long-term nitrogen enrichment

Author

Mao, Jinhua, Mao, Qinggong, Gundersen, Per, Gurmesa, Geshere A., Zhang, Wei, Huang, Juan, Wang, Senhao, Li, Andi, Wang, Yufang, Guo, Yabing, Liu, Rongzhen, Mo, Jiangming, Zheng, Mianhai, Mao, Jinhua, Mao, Qinggong, Gundersen, Per, Gurmesa, Geshere A., Zhang, Wei, Huang, Juan, Wang, Senhao, Li, Andi, Wang, Yufang, Guo, Yabing, Liu, Rongzhen, Mo, Jiangming, and Zheng, Mianhai

Abstract

The responses of forests to nitrogen (N) deposition largely depend on the fates of deposited N within the ecosystem. Nitrogen-fixing legume trees widely occur in terrestrial forests, but the fates of deposited N in legume-dominated forests remain unclear, which limit a global evaluation of N deposition impacts and feedbacks on carbon sequestration. Here, we performed the first ecosystem-scale 15N labeling experiment in a typical legume-dominated forest as well as in a nearby non-legume forest to determine the fates of N deposition between two different forest types and to explore their underlying mechanisms. The 15N was sprayed bimonthly for 1 year to the forest floor in control and N addition (50 kg N ha−1 year−1 for 10 years) plots in both forests. We unexpectedly found a strong capacity of the legume forest to retain deposited N, with 75 ± 5% labeled N recovered in plants and soils, which was higher than that in the non-legume forest (56 ± 4%). The higher 15N recovery in legume forest was mainly driven by uptake by the legume trees, in which 15N recovery was approximately 15% more than that in the nearby non-legume trees. This indicates higher N-demand by the legume than non-legume trees. Mineral soil was the major sink for deposited N, with 39 ± 4% and 34 ± 3% labeled N retained in the legume and non-legume forests, respectively. Moreover, N addition did not significantly change the 15N recovery patterns of both forests. Overall, these findings indicate that legume-dominated forests act as a strong sink for deposited N regardless of high soil N availability under long-term atmospheric N deposition, which suggest a necessity to incorporate legume-dominated forests into N-cycling models of Earth systems to improve the understanding and prediction of terrestrial N budgets and the global N deposition effects.

Published
2022

20. Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study

Author

Li, Qi, primary, Cao, Mengran, additional, Yuan, Guosheng, additional, Cheng, Xiao, additional, Zang, Mengya, additional, Chen, Ming, additional, Hu, Xiaoyun, additional, Huang, Jing, additional, Li, Rong, additional, Guo, Yabing, additional, Ruan, Jian, additional, and Chen, Jinzhang, additional

Published
2022
Full Text
View/download PDF

22. AdvanTIG-206: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (BGB-A1217; OCI) plus anti-programmed cell death protein 1 (PD-1) mAb tislelizumab (TIS) plus BAT1706 versus (vs) TIS plus BAT1706 as first-line treatment for advanced hepatocellular carcinoma (HCC).

Author

Fan, Jia, primary, Ren, Zhenggang, additional, Hsu, Chiun, additional, Guo, Yabing, additional, Song, Tianqiang, additional, Wang, Wentao, additional, Chao, Yee, additional, Gao, Yujuan, additional, Li, Bai, additional, Ferro, Salvatore, additional, and Yen, Chia-Jui, additional

Published
2022
Full Text
View/download PDF

23. TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma.

Author

Kudo, Masatoshi, primary, Guo, Yabing, additional, Hua, Yongqiang, additional, Zhao, Ming, additional, Xing, Wenge, additional, Zhang, Yonghong, additional, Liu, Ruibao, additional, Ren, Zhenggang, additional, Gu, Shanzhi, additional, Lin, Zhengyu, additional, Lv, Weifu, additional, Wang, Yumeng, additional, and Dong, Jiahong, additional

Published
2022
Full Text
View/download PDF

24. Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC).

Author

Zhang, Feng, primary, Bai, Yuxian, additional, Fang, Weijia, additional, Meng, Zhiqiang, additional, Xiong, Jianping, additional, Guo, Yabing, additional, Zhang, Tao, additional, Zhang, Jingdong, additional, Ying, Jieer, additional, Chen, Zhendong, additional, Ren, Zhenggang, additional, Chen, Yajin, additional, Hao, Chunyi, additional, Yang, Liu, additional, Wang, Jun, additional, Zhang, Juan, additional, Yu, Fan, additional, Fei, Cong, additional, Wu, Xikun, additional, and Qin, Shukui, additional

Published
2022
Full Text
View/download PDF

25. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy

Author

Liu, Shi, primary, Deng, Rui, additional, Zhou, Bin, additional, Liang, Xieer, additional, Liu, Zhihong, additional, Peng, Jie, additional, Chen, Jinjun, additional, Zhou, Yuanping, additional, Guo, Yabing, additional, Chen, Yongpeng, additional, Li, Wanying, additional, Shen, Sheng, additional, Lu, Xingyu, additional, Zhao, Siru, additional, Liao, Xingmei, additional, Liang, Hongyan, additional, Lan, Yu, additional, Hou, Jinlin, additional, Fan, Rong, additional, and Sun, Jian, additional

Published
2021
Full Text
View/download PDF

26. Unexpected high retention of 15 N‐labeled nitrogen in a tropical legume forest under long‐term nitrogen enrichment

Author

Mao, Jinhua, primary, Mao, Qinggong, additional, Gundersen, Per, additional, Gurmesa, Geshere A., additional, Zhang, Wei, additional, Huang, Juan, additional, Wang, Senhao, additional, Li, Andi, additional, Wang, Yufang, additional, Guo, Yabing, additional, Liu, Rongzhen, additional, Mo, Jiangming, additional, and Zheng, Mianhai, additional

Published
2021
Full Text
View/download PDF

28. Transarterial infusion chemotherapy with FOLFOX for advanced hepatocellular carcinoma: a multi-center propensity score matched analysis of real-world practice

Author

Li, Shaohua, primary, Mei, Jie, additional, Wang, Qiaoxuan, additional, Shi, Feng, additional, Liu, Hongyan, additional, Zhao, Ming, additional, Lu, Lianghe, additional, Ling, Yihong, additional, Guo, Zhixing, additional, Guo, Yabing, additional, Chen, Xiaoming, additional, Shi, Ming, additional, Lau, Wan Yee, additional, Wei, Wei, additional, and Guo, Rongping, additional

Published
2021
Full Text
View/download PDF

29. Association of Serum Hepatitis B Virus RNA With Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients Under Nucleos(t)ide Analogues Therapy.

Author

Liu, Shi, Deng, Rui, Zhou, Bin, Liang, Xieer, Liu, Zhihong, Peng, Jie, Chen, Jinjun, Zhou, Yuanping, Guo, Yabing, Chen, Yongpeng, Li, Wanying, Shen, Sheng, Lu, Xingyu, Zhao, Siru, Liao, Xingmei, Liang, Hongyan, Lan, Yu, Hou, Jinlin, Fan, Rong, and Sun, Jian

Subjects
LIVER tumors, DNA, NUCLEOSIDES, HEPATITIS viruses, RNA, ANTIVIRAL agents, RESEARCH funding, CHRONIC hepatitis B, HEPATOCELLULAR carcinoma, LONGITUDINAL method, PHARMACODYNAMICS, DISEASE complications
Abstract

Background: Whether serum hepatitis B virus (HBV) RNA associates with hepatocellular carcinoma (HCC) development in chronic hepatitis B (CHB) patients has not been fully elucidated.Methods: We enrolled 2974 patients receiving nucleos(t)ide analogues (NAs) from a prospective, observational CHB cohort to investigate the effect of serum HBV RNA, measured at study entry (baseline), on HCC development, using Cox regression analyses.Results: During median follow-up of 4.4 years, 90 patients developed HCC. Patients with detectable baseline HBV RNA (n = 2072) exhibited significantly higher HCC risk than those with undetectable level (5-year HCC incidence estimated by Kaplan-Meier method: 4.1% versus 1.8%, P = .009; adjusted hazard ratio [aHR] = 2.21, P = .005). HBV RNA levels of 609-99 999 and ≥100 000 copies/mL were associated with incrementally increasing HCC risk (aHR = 2.15 and 3.05, respectively; P for trend = .003), compared to undetectable level (<609 copies/mL). Moreover, patients with single-detectable either HBV DNA or RNA and double-detectable DNA and RNA had 1.57- and 4.02-fold higher HCC risk, respectively, than those with double-undetectable DNA and RNA (P for trend = .001).Conclusions: High-level HBV RNA is associated with increased HCC risk in NAs-treated patients. Achieving undetectable HBV RNA may contribute to better clinical outcomes, indicating it could be a valuable endpoint of anti-HBV treatment. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

30. Unexpected high retention of 15N‐labeled nitrogen in a tropical legume forest under long‐term nitrogen enrichment.

Author

Mao, Jinhua, Mao, Qinggong, Gundersen, Per, Gurmesa, Geshere A., Zhang, Wei, Huang, Juan, Wang, Senhao, Li, Andi, Wang, Yufang, Guo, Yabing, Liu, Rongzhen, Mo, Jiangming, and Zheng, Mianhai

Subjects
TROPICAL forests, LEGUMES, FOREST soils, CARBON sequestration, ATMOSPHERIC deposition, SOIL mineralogy, PLANT-soil relationships
Abstract

The responses of forests to nitrogen (N) deposition largely depend on the fates of deposited N within the ecosystem. Nitrogen‐fixing legume trees widely occur in terrestrial forests, but the fates of deposited N in legume‐dominated forests remain unclear, which limit a global evaluation of N deposition impacts and feedbacks on carbon sequestration. Here, we performed the first ecosystem‐scale 15N labeling experiment in a typical legume‐dominated forest as well as in a nearby non‐legume forest to determine the fates of N deposition between two different forest types and to explore their underlying mechanisms. The 15N was sprayed bimonthly for 1 year to the forest floor in control and N addition (50 kg N ha−1 year−1 for 10 years) plots in both forests. We unexpectedly found a strong capacity of the legume forest to retain deposited N, with 75 ± 5% labeled N recovered in plants and soils, which was higher than that in the non‐legume forest (56 ± 4%). The higher 15N recovery in legume forest was mainly driven by uptake by the legume trees, in which 15N recovery was approximately 15% more than that in the nearby non‐legume trees. This indicates higher N‐demand by the legume than non‐legume trees. Mineral soil was the major sink for deposited N, with 39 ± 4% and 34 ± 3% labeled N retained in the legume and non‐legume forests, respectively. Moreover, N addition did not significantly change the 15N recovery patterns of both forests. Overall, these findings indicate that legume‐dominated forests act as a strong sink for deposited N regardless of high soil N availability under long‐term atmospheric N deposition, which suggest a necessity to incorporate legume‐dominated forests into N‐cycling models of Earth systems to improve the understanding and prediction of terrestrial N budgets and the global N deposition effects. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer.

Author

Li J, Bai Y, Chen Z, Ying J, Guo Y, Fang W, Zhang F, Xiong J, Zhang T, Meng Z, Zhang J, Ren Z, Hao C, Chen Y, Lin X, Pan H, Zhou F, Li X, Yu F, Zhang J, Zhang Z, and Qin S

Subjects
Humans, Male, Female, Aged, Middle Aged, Adult, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols pharmacology, Esophageal Neoplasms drug therapy, Esophageal Neoplasms pathology, Aged, 80 and over, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized pharmacology, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular pathology, Liver Neoplasms drug therapy, Stomach Neoplasms drug therapy, Stomach Neoplasms pathology, Esophagogastric Junction pathology
Abstract

Background: Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MER), VEGFR-2, KIT, and MET. SAFFRON-104 (NCT03941873) was a multicohort phase Ib/II study investigating sitravatinib with/without tislelizumab, an anti-programmed cell death protein 1 (PD-1) antibody, in patients with advanced hepatocellular carcinoma (HCC) or gastric cancer/gastroesophageal junction cancer (GC/GEJC)., Methods: Eligible patients had histologically/cytologically confirmed advanced HCC or GC/GEJC. Phase I determined the recommended phase II dose (RP2D) of sitravatinib with/without tislelizumab. Phase II evaluated sitravatinib monotherapy in patients with pretreated HCC, and sitravatinib plus tislelizumab in anti-PD-(L)1-naïve or -treated HCC and anti-PD-(L)1-naïve GC/GEJC. Primary endpoints were safety/tolerability (phase I) and objective response rate (ORR) (phase II)., Results: At data cutoff (March 31, 2023), 111 patients were enrolled; 102 were efficacy-evaluable (median study follow-up 9.1 months [range: 0.7-36.9]). The RP2D of sitravatinib was determined as 120 mg orally once daily. In patients receiving sitravatinib monotherapy and sitravatinib in combination with tislelizumab, grade ≥ 3 treatment-related adverse events occurred in 14 (51.9%) and 42 (50.0%) patients, respectively. The ORR was 25% (95% confidence interval [CI]: 8.7-49.1) in patients with pretreated HCC receiving sitravatinib monotherapy. In patients receiving sitravatinib with tislelizumab, the ORR was 11.5% (95% CI 2.4-30.2) with anti-PD-(L)1-naïve HCC, 9.5% (95% CI 1.2-30.4) with anti-PD-(L)1-treated HCC, and 16.1% (95% CI 5.5-33.7) in patients with anti-PD-(L)1-naïve GC/GEJC., Conclusions: Sitravatinib with/without tislelizumab was generally well tolerated and showed preliminary antitumor activity in patients with advanced HCC and GC/GEJC., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

35. Efficacy and safety of tislelizumab plus lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma: a multicenter, single-arm, phase 2 trial.

Author

Xu L, Chen J, Liu C, Song X, Zhang Y, Zhao H, Yan S, Jia W, Wu Z, Guo Y, Yang J, Gong W, Ma Y, Yang X, Gao Z, Zhang N, Zheng X, Li M, Su D, and Chen M

Subjects
Humans, Male, Female, Middle Aged, Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols adverse effects, Treatment Outcome, Adult, Carcinoma, Hepatocellular drug therapy, Quinolines therapeutic use, Quinolines adverse effects, Quinolines administration & dosage, Liver Neoplasms drug therapy, Phenylurea Compounds therapeutic use, Phenylurea Compounds adverse effects, Phenylurea Compounds administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Antibodies, Monoclonal, Humanized adverse effects, Antibodies, Monoclonal, Humanized administration & dosage
Abstract

Background: Lenvatinib is widely used in treatment of unresectable hepatocellular carcinoma (uHCC), but the benefit of its combination with immunotherapy needs to be verified. This study evaluated the efficacy and safety of tislelizumab plus lenvatinib in systemic treatment-naïve patients with uHCC., Methods: In this multicenter, single-arm, phase 2 study, systemic treatment-naïve patients with uHCC received tislelizumab 200 mg every three weeks plus lenvatinib (bodyweight ≥ 60 kg: 12 mg; < 60 kg: 8 mg; once daily). Dose-limiting toxicities (DLTs) were evaluated in safety run-in phase to determine whether to enter the expansion phase. The primary endpoint was objective response rate (ORR) assessed by independent review committee (IRC) per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST v1.1). Based on Simon's two-stage design, > 6 responders were needed in stage 1 (n = 30) to continue the study, and ≥ 18 responders were needed by the end of stage 2 (n = 60) to demonstrate statistical superiority to a historical control of lenvatinib monotherapy., Results: Sixty-four patients were enrolled. No DLTs were reported. The study achieved statistical superiority (p = 0.0003) with 23 responders assessed by IRC per RECIST v1.1 in the first 60 patients of the efficacy evaluable analysis set (n = 62). After a median follow-up of 15.7 months, confirmed ORR and disease control rate were 38.7% (24/62, 95% confidence interval [CI], 26.6-51.9) and 90.3% (56/62, 95% CI, 80.1-96.4), respectively. Median progression-free survival was 8.2 months (95% CI, 6.8-not evaluable). Overall survival rate at 12 months was 88.6% (95% CI, 77.7-94.4). Grade ≥ 3 treatment-related adverse events occurred in 18 (28.1%) patients., Conclusions: Tislelizumab plus lenvatinib demonstrated promising antitumor activity with favourable tolerability as first-line therapy for patients with uHCC., Trial Registration: ClinicalTrials.gov (NCT04401800)., (© 2024. The Author(s).)

Published
2024
Full Text
View/download PDF

36. Unexpected high retention of 15 N-labeled nitrogen in a tropical legume forest under long-term nitrogen enrichment.

Author

Mao J, Mao Q, Gundersen P, Gurmesa GA, Zhang W, Huang J, Wang S, Li A, Wang Y, Guo Y, Liu R, Mo J, and Zheng M

Subjects
Ecosystem, Forests, Soil, Trees physiology, Fabaceae, Nitrogen
Abstract

The responses of forests to nitrogen (N) deposition largely depend on the fates of deposited N within the ecosystem. Nitrogen-fixing legume trees widely occur in terrestrial forests, but the fates of deposited N in legume-dominated forests remain unclear, which limit a global evaluation of N deposition impacts and feedbacks on carbon sequestration. Here, we performed the first ecosystem-scale 15 N labeling experiment in a typical legume-dominated forest as well as in a nearby non-legume forest to determine the fates of N deposition between two different forest types and to explore their underlying mechanisms. The 15 N was sprayed bimonthly for 1 year to the forest floor in control and N addition (50 kg N ha -1  year -1 for 10 years) plots in both forests. We unexpectedly found a strong capacity of the legume forest to retain deposited N, with 75 ± 5% labeled N recovered in plants and soils, which was higher than that in the non-legume forest (56 ± 4%). The higher 15 N recovery in legume forest was mainly driven by uptake by the legume trees, in which 15 N recovery was approximately 15% more than that in the nearby non-legume trees. This indicates higher N-demand by the legume than non-legume trees. Mineral soil was the major sink for deposited N, with 39 ± 4% and 34 ± 3% labeled N retained in the legume and non-legume forests, respectively. Moreover, N addition did not significantly change the 15 N recovery patterns of both forests. Overall, these findings indicate that legume-dominated forests act as a strong sink for deposited N regardless of high soil N availability under long-term atmospheric N deposition, which suggest a necessity to incorporate legume-dominated forests into N-cycling models of Earth systems to improve the understanding and prediction of terrestrial N budgets and the global N deposition effects., (© 2021 John Wiley & Sons Ltd.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results